Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In 3D Systems To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in 3D System between August 13, 2024 and May 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 28, 2025 (GLOBE ...

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- , June 27, 2025 – Levi & Korsinsky, LLP notifies investors in 3D Systems Corporation ("3D Systems Corporation" or the "Company") (NYSE: DDD) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of 3D Systems Corporation investors who were adversely affected by alleged securities fraud between August 13, 2024 and May 12, 2025. Follow the link below to get more information and be contacted by a member of our team: htt ...

Group 1 - The article initiates coverage on 3D Systems Corporation (NYSE: DDD) with a Strong Buy rating and a price target of $4, highlighting its end-to-end additive manufacturing and digital manufacturing capabilities across various sectors including healthcare, dental, aerospace, and biotech [1] - Moretus Research focuses on identifying companies with durable business models, mispriced cash flow potential, and intelligent capital allocation, applying a structured framework to deliver high-quality equity research [1] - The valuation approach used by Moretus Research emphasizes pragmatic, sector-relevant multiples tailored to each company's business model and capital structure, aiming for comparability, simplicity, and relevance [1] Group 2 - Research coverage by Moretus tends to favor underappreciated companies undergoing structural change or temporary dislocation, where disciplined analysis can lead to asymmetric returns [1] - Moretus Research aims to raise the standard for independent investment research by providing professional-grade insights, actionable valuation, and a strong filter for what truly matters in modern equity analysis [1]

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation, alleging that the company made misleading statements regarding its financial health and the impact of customer spending on its business [3][4]. Group 1: Class Action Details - The class action represents investors who purchased securities between August 13, 2024, and May 12, 2025, with a deadline of August 12, 2025, to file a lead plaintiff motion [1]. - The Portnoy Law Firm is offering complimentary case evaluations to investors seeking to recover losses [2]. Group 2: Allegations Against 3D Systems - The lawsuit claims that 3D Systems understated the impact of weakened customer spending and overstated its resilience to market challenges [3]. - It is alleged that changes in the partnership with United Therapeutics Corporation would negatively affect revenue from the Regenerative Medicine Program [3]. Group 3: Financial Performance - On March 26, 2025, 3D Systems reported a Q4 non-GAAP loss of $0.19 per share, missing consensus estimates by $0.08, with Q4 revenue of $111 million, down 3.4% year-over-year [6]. - The full-year revenue for 2024 was reported at $440.1 million, reflecting a 10% decline year-over-year due to lower hardware sales and macroeconomic challenges [6]. - Following the Q1 2025 results announcement on May 12, 2025, the stock fell more than 26%, with a reported net loss of $37 million, more than double the loss from Q1 2024 [4][6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of 3D Systems Corporation regarding a class action lawsuit due to alleged misleading statements and omissions made by the company during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from August 13, 2024, to May 12, 2025 [3]. - Allegations include that 3D Systems understated the impact of weakened customer spending and overstated its resilience in challenging industry conditions [3]. - Additionally, the updated milestone criteria in the partnership with United Therapeutics Corporation are claimed to negatively impact the company's regenerative medicine program revenue [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of August 12, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to deceitful practices by companies [5]. - The firm emphasizes the importance of responsible business practices and good corporate citizenship [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of 3D Systems Corporation regarding a class action lawsuit due to alleged misleading statements and omissions made by the company during the specified class period [1]. Group 1: Allegations - The complaint alleges that 3D Systems understated the impact of weakened customer spending on its business while overstating its resilience in challenging industry conditions [1]. - It is also claimed that updated milestone criteria in the partnership with United Therapeutics Corporation would negatively affect the revenue from the company's regenerative medicine program [1]. - As a result, the company's public statements were deemed materially false and misleading throughout the relevant period [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as August 13, 2024, to May 12, 2025 [1]. - Shareholders are encouraged to register for the class action by the deadline of August 12, 2025, to potentially become lead plaintiffs [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is recognized nationally for its commitment to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of the company's stock [3].

Core Insights - 3D Systems has achieved FDA approval for a 3D bioprinting solution for the regenerative repair of peripheral nerve damage, in collaboration with TISSIUM [1][4] - The newly developed device, COAPTIUM® CONNECT with TISSIUM Light, is a bioabsorbable, atraumatic, and sutureless solution for nerve repair, marking a significant milestone in the industry [1][4] - The global 3D bioprinting market is projected to grow from $1.3 billion in 2024 to $2.4 billion by 2029, indicating strong growth potential for the sector [3] Company Developments - 3D Systems has been a leader in bioprinting for nearly a decade, focusing on developing technologies for regenerative medicine and personalized healthcare [2][3] - The company has collaborated with United Therapeutics Corporation since 2017 to create an unlimited supply of human lungs for transplantation, showcasing its commitment to advancing medical solutions [2][3] - 3D Systems has produced over two million implants and instruments for more than 100 CE-marked and FDA-cleared devices, demonstrating its extensive experience in the medical device sector [3] Industry Impact - The collaboration with TISSIUM sets a new standard for high-resolution elastomeric 3D-printed medical implants, enhancing the capabilities of bioprinting technologies [4] - 3D Systems' innovations in bioprinting are expected to transform patient care by enabling the fabrication of living tissues and developing new therapeutics [5] - The advancements in 3D bioprinting are anticipated to accelerate the adoption of additive manufacturing in the medical field, contributing to improved healthcare delivery [4][5]

Core Viewpoint - 3D Systems has successfully completed strategic transactions to refinance its outstanding convertible notes and repurchase shares, enhancing its capital structure and financial flexibility [1][4]. Group 1: Financial Transactions - The company repurchased approximately 8 million shares of its common stock, representing about 6% of its outstanding shares as of May 2, 2025 [1][7]. - The refinancing involved retiring approximately $88 million of debt, which is 41% of the prior balance, at a significant discount to par [7]. - The company issued $92 million in new Convertible Senior Secured Notes due in 2030, with an interest rate of 5.875% per annum [2][7]. Group 2: Financial Impact - The repurchase of existing notes at a discount is expected to result in a gain of approximately $10 million in the second quarter financial statements [3]. - The transactions are anticipated to reduce overall outstanding debt and extend the maturity profile, providing enhanced financial flexibility [4][7]. Group 3: Management Commentary - Dr. Jeffrey Graves, president and CEO, emphasized that these transactions are a significant step in strengthening the company's capital structure and managing potential dilution through share repurchase [4]. - The company has reduced its total debt by over 72% since 2021 through opportunistic transactions [4]. Group 4: Future Outlook - The company maintains strong cash reserves to support ongoing restructuring efforts and key growth initiatives [7]. - The new notes will mature on June 15, 2030, unless converted or repurchased earlier, reflecting a strategic move to manage debt maturity [2][7].

Core Viewpoint - A class action securities lawsuit has been filed against 3D Systems Corporation, alleging securities fraud that affected investors between August 13, 2024, and May 12, 2025 [1][2]. Summary by Sections Class Action Details - The lawsuit claims that 3D Systems Corporation made false statements regarding the impact of reduced customer spending and overstated its resilience in difficult market conditions [2]. - It is also alleged that changes in the partnership with United Therapeutics Corporation would adversely affect the revenue from the Company's regenerative medicine program [2]. Next Steps for Investors - Investors who suffered losses during the specified period have until August 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Group 1 - The Schall Law Firm has initiated a class action lawsuit against 3D Systems Corporation for violations of the Securities Exchange Act of 1934 [1][4] - The lawsuit pertains to investors who purchased 3D Systems securities between August 13, 2024, and May 13, 2025 [2] - The complaint alleges that 3D Systems made false and misleading statements regarding the impact of weakening customer spending and the performance of its Regenerative Medicine Program [4] Group 2 - Investors are encouraged to contact the Schall Law Firm to discuss their rights and potential participation in the lawsuit [3][5] - The class in this case has not yet been certified, meaning that potential class members are not yet represented by an attorney [3] - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [5]